Revelation Biosciences, Inc. (NASDAQ:REVB) Shares Shorted: Short Interest Up 93.7% in October

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large increase in short interest in October. As of October 30th, there was short interest totaling 12,792 shares, an increase of 93.7% from the October 15th total of 6,605 shares. Based on an average daily trading volume, of 39,572 shares, the short-interest ratio is currently 0.3 days. Approximately 2.0% of the shares of the company are sold short.

Revelation Biosciences Trading Down 1.1%

Revelation Biosciences stock traded down $0.05 during mid-day trading on Friday, hitting $4.33. The stock had a trading volume of 6,579 shares, compared to its average volume of 27,757. Revelation Biosciences has a one year low of $3.08 and a one year high of $40.60. The firm has a market capitalization of $2.95 million, a P/E ratio of -0.10 and a beta of -0.13. The firm’s 50 day moving average is $5.16 and its 200 day moving average is $7.42.

Revelation Biosciences (NASDAQ:REVB) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($5.92) EPS for the quarter, beating analysts’ consensus estimates of ($6.16) by $0.24. As a group, equities research analysts forecast that Revelation Biosciences will post -24.53 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases. Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.